These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 9638122)

  • 21. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
    Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
    Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic implications of evidence-based prescribing for hypertension: can better care cost less?
    Fischer MA; Avorn J
    JAMA; 2004 Apr; 291(15):1850-6. PubMed ID: 15100203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: interrupted time-series analysis.
    Fretheim A; Håvelsrud K; MacLennan G; Kristoffersen DT; Oxman AD
    PLoS Med; 2007 Jul; 4(7):e232. PubMed ID: 17622192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension.
    Hilleman DE; Mohiuddin SM; Lucas BD; Stading JA; Stoysich AM; Ryschon K
    Clin Ther; 1994; 16(1):88-102; discussion 87. PubMed ID: 7911403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service.
    Marković BB; Kranjcević K; Reiner Z; Blazeković SM; Spehar SS
    Croat Med J; 2005 Dec; 46(6):984-9. PubMed ID: 16342354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood pressure control and drug therapy in patients with diagnosed hypertension: a survey in Italian general practice.
    Filippi A; Paolini I; Innocenti F; Mazzaglia G; Battaggia A; Brignoli O
    J Hum Hypertens; 2009 Nov; 23(11):758-63. PubMed ID: 19242492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International variation in prescribing antihypertensive drugs: its extent and possible explanations.
    Fretheim A; Oxman AD
    BMC Health Serv Res; 2005 Mar; 5(1):21. PubMed ID: 15762983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug prescribing for hypertension at primary healthcare facilities in Trinidad.
    Clement YN; Ali S; Harripaulsingh S; Lacaille K; Mohammed O; Mohammed S; Ragbir T; Ramirez E; Tshiamo K
    West Indian Med J; 2012 Jan; 61(1):43-8. PubMed ID: 22808565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
    Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
    Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications.
    De Natale R; Draghi E; Dorigo MT
    Acta Ophthalmol Scand; 2004 Aug; 82(4):393-6. PubMed ID: 15291930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effective therapy for hypertension.
    Barrie W
    West J Med; 1996 Apr; 164(4):303-9. PubMed ID: 8732729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects and cost-effectiveness of a guideline-oriented primary healthcare hypertension management program in Beijing, China: results from a 1-year controlled trial.
    Wang X; Li W; Li X; An N; Chen H; Jan S; Ming G; Hua Q; Yan X; Sun N; Zhao D; Wu Y
    Hypertens Res; 2013 Apr; 36(4):313-21. PubMed ID: 23154592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescribing patterns and cost of antihypertensive drugs in an internal medicine clinic.
    Jhaj R; Goel NK; Gautam CS; Hota D; Sangeeta B; Sood A; Sachdev A
    Indian Heart J; 2001; 53(3):323-7. PubMed ID: 11516032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rational prescribing and cost reduction in the treatment of arterial hypertension: a simulation exercise].
    Bonet A; Gosalbes V; Fito M; Navarro J
    Gac Sanit; 2001; 15(4):327-35. PubMed ID: 11578562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003.
    Chiang CW; Chen CY; Chiu HF; Wu HL; Yang CY
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):412-21. PubMed ID: 17252613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescribing trends and drug budget impact of the ARBs in the UK.
    Blak BT; Mullins CD; Shaya FT; Simoni-Wastila L; Cooke CE; Weir MR
    Value Health; 2009; 12(2):302-8. PubMed ID: 18647253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economics of suboptimal drug use: cost-savings of using JNC-recommended medications for management of uncomplicated essential hypertension.
    Xu KT; Moloney M; Phillips S
    Am J Manag Care; 2003 Aug; 9(8):529-36. PubMed ID: 12921230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of drug cost on hypertension treatment decision.
    Salman H; Bergman M; Hart J; Neuman V; Zevin D; Bessler H; Djaldetti M
    Public Health; 1999 Sep; 113(5):243-6. PubMed ID: 10557119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care.
    Counterweight Project Team
    J Health Serv Res Policy; 2008 Jul; 13(3):158-66. PubMed ID: 18573765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.